MRNS
MARINUS PHARMACEUTICALS INC
About MRNS
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company, which is focused on the development of therapeutics for seizure disorders. The Company's commercial product, ZTALMY (ganaxolone) oral suspension CV for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The Company's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. The Company’s ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Buy US stocks in Australia starting with MRNS. Open an account and start investing today!
$297.99M
-
0.00%
414.69K
$6.30
$5.98
$6.07
$10.94
$3.47
MRNS FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in MRNS
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.